Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB:BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announces the release of a white paper on China's Traditional Chinese Medicine Market by market analyst Arthur Goldgaber of SmallcapInsights.com.

Entitled ?Health Care Reform in China Boosts Sales of Traditional Chinese Medicine,? the white paper describes China's efforts to provide affordable, higher-quality healthcare (including TCM products) to all its citizens and the massive reforms that are currently taking place to make this a reality.

From the white paper, ?As a result of the reforms, the Chinese government is paying up to 90% of certain pharmaceutical products' costs. These policies are opening up the pharmaceutical industry in China to a target demographic of approximately 900 million rural Chinese, who for the most part, have not been able to purchase medicines on a large scale due to their limited income.?

The paper goes on to say, ?For patients on the BMI system (about 180 million, most of urban residents), the government reimburses 70-90% of the cost of drugs listed on the NDRL. (The NDRL is also used by the other major state-run medical insurance systems, including programs for rural residents, the military and students.) As a result, patients often prefer, or even demand, a listed NDRL drug over others that could be prescribed.?

Bohai currently has the rights to produce 17 NDRL medicines, including Bohai's top three medicines, which represent over 75% of Bohai's total sales.

The publication of the white paper is a part of Bohai's continuing investor outreach and education program. To view the full white paper (free of charge, in PDF format), please visit: http://www.bohaipharma.com/events.html.

About Bohai Pharmaceuticals Group, Inc.

Based in the city of Yantai, Shandong Province, China, Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on Traditional Chinese Medicine in China. Bohai's medicines address common health problems such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. Bohai's products are sold either by prescription through hospitals or over-the-counter through local pharmacies and retail drug store chains. Bohai has approximately 600 employees, including approximately 300 sales representatives, operating from 20 offices throughout China. Bohai's three lead products, Tongbi Capsules, Tongbi Tablets and Lung Nourishing Cream, are eligible for reimbursement under China's National Medical Insurance Program.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Fact Sheet and Overview Video.

For additional information, please visit Bohai's corporate website: www.bohaipharma.com.

SEC Section 17(b) Disclosure

SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. (?Trilogy?). Trilogy has been engaged by Bohai Pharmaceuticals Group, Inc. ("BOPH") to provide investor relations services for compensation of a monthly retainer in the amount of $12,500. Upon execution of the agreement on January 5th 2010, Trilogy Capital Partners also owned 31,250 shares of common stock of BOPH. In addition, Alfonso J. Cervantes, a principal of Trilogy, beneficially owned 90,000 shares of common stock of BOPH through La Mancha Capital Group, LLC, a limited liability company, and is a non-managing member of Regeneration Capital Group, LLC, which owned 541,875 shares of common stock of BOPH.

Although the white paper described herein was commissioned and paid for by Bohai Pharmaceuticals Group, Inc., the company notes that the paper was generated independently by the author, and statements by the author are his own and not attributable to Bohai Pharmaceuticals Group, Inc. Readers are advised to review the white paper in its entirety, including the disclosures and disclaimers noted therein.

Additional Information Relating to Bohai's Trading Data

Due to certain recent disruptions in the marketplace relating to quotations on the OTC Bulletin Board operated by FINRA (OTCBB), incomplete trading data may exist for certain companies like Bohai. Real-time trading data for Bohai on the OTCQB market is available through the below link. Readers are advised that OTCQB market is operated by the owner of otcmarkets.com, and Bohai Pharmaceuticals Group, Inc. makes no representation or warranty regarding the OTCQB market.

For real-time trading data for Bohai on the OTCQB market, including Level 2 quotes, please visit: www.otcmarkets.com/stock/boph/quote.

Cautionary Note Regarding Forward-Looking Statements

This press release, the white paper referred to herein and the statements of representatives of Bohai Pharmaceuticals Group, Inc. (the ?Company?) related thereto contain, or may contain, among other things, ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are ?forward-looking statements,? including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as ?guidance,? ?projects,? ?may,? ?could,? ?would,? ?should,? ?believes,? ?expects,? ?anticipates,? ?estimates,? ?intends,? ?plans,? ?ultimately? or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.

Company Contact:
Bohai Pharmaceuticals Group, Inc.
Gene Hsiao, Chief Financial Officer
856-499-4475
or
Investor Relations Contacts:
The Trout Group
Danielle Spangler, 646-378-2924
or
Trilogy Capital Partners - Asia
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com